the FDA
West Virginia would back ibogaine trials with state grants
Delegate Ryan Browning’s bill would let the health secretary fund public-private studies aimed at winning federal approval for ibogaine as a treatment for opioid use disorder and related conditions.
West Virginia lawmakers are weighing a state grant program for ibogaine research. The proposal would have the Secretary of Health support trials that could help the drug move toward federal approval.
- House Bill 4626 would create a grant program for ibogaine trials.
- The Secretary of Health would run the funding program.
- The goal is Food and Drug Administration approval for addiction and mental health uses.
- In West Virginia, House Bill 4626 would create a grant program run by the Secretary of Health to pay for public-private drug-development trials with ibogaine
- The bill is aimed at helping move the compound through Food and Drug Administration approval for use against opioid use disorder, co-occurring substance use disorder and other neurological or mental health conditions where ibogaine shows efficacy
In West Virginia, House Bill 4626 would create a grant program run by the Secretary of Health to pay for public-private drug-development trials with ibogaine. The bill is aimed at helping move the compound through Food and Drug Administration approval for use against opioid use disorder, co-occurring substance use disorder and other neurological or mental health conditions where ibogaine shows efficacy.
A state wager on a new treatment path
The proposal does not just treat ibogaine as a research topic. It turns the compound into a state-backed bet that clinical trials could build enough evidence for the FDA to consider it as a treatment option for some of the most stubborn addiction and brain-health problems.